Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Moore

Showing results (1131-1140 of 1,231) with videos related to

Pageof 124
Sort By:
Physical Review Letters|October 10, 2006
K isomers in 254No: probing single-particle energies and pairing strengths in the heaviest nucleiS K Tandel, T L Khoo, D Seweryniak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2019
Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)Christine B Ambrosone, Gary R Zirpoli, Alan D Hutson, et al.
Leukemia & Lymphoma|February 28, 2015
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997David M Lucas, Amy S Ruppert, Gerard Lozanski, et al.
Journal of the National Cancer Institute|April 3, 2020
Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With SurvivalRikki A Cannioto, Alan Hutson, Shruti Dighe, et al.
The Pharmacogenomics Journal|September 4, 2013
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancerS Yao, L E Sucheston, H Zhao, et al.
Breast Cancer Research and Treatment|July 19, 2011
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)Lara E Sucheston, Hua Zhao, Song Yao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2014
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancerGeorge T Budd, William E Barlow, Halle C F Moore, et al.
Veterinary Immunology and Immunopathology|June 25, 1998
Report of the Second Equine Leucocyte Antigen Workshop, Squaw valley, California, July 1995D P Lunn, M A Holmes, D F Antczak, et al.
Physical Review Letters|October 13, 2007
New determination of the astrophysical S factor SE1 of the 12C(alpha,gamma)16O reactionX D Tang, K E Rehm, I Ahmad, et al.
Physical Review Letters|February 21, 2006
Breakdown of K selection in 178HfA B Hayes, D Cline, C Y Wu, et al.
Pageof 124

Showing results (1131-1140 of 1,231) with videos related to

Sort By:
Pageof 124
Physical Review Letters|October 10, 2006
K isomers in 254No: probing single-particle energies and pairing strengths in the heaviest nucleiS K Tandel, T L Khoo, D Seweryniak, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2019
Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221)Christine B Ambrosone, Gary R Zirpoli, Alan D Hutson, et al.
Leukemia & Lymphoma|February 28, 2015
Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997David M Lucas, Amy S Ruppert, Gerard Lozanski, et al.
Journal of the National Cancer Institute|April 3, 2020
Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With SurvivalRikki A Cannioto, Alan Hutson, Shruti Dighe, et al.
The Pharmacogenomics Journal|September 4, 2013
Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancerS Yao, L E Sucheston, H Zhao, et al.
Breast Cancer Research and Treatment|July 19, 2011
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221)Lara E Sucheston, Hua Zhao, Song Yao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 26, 2014
SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancerGeorge T Budd, William E Barlow, Halle C F Moore, et al.
Veterinary Immunology and Immunopathology|June 25, 1998
Report of the Second Equine Leucocyte Antigen Workshop, Squaw valley, California, July 1995D P Lunn, M A Holmes, D F Antczak, et al.
Physical Review Letters|October 13, 2007
New determination of the astrophysical S factor SE1 of the 12C(alpha,gamma)16O reactionX D Tang, K E Rehm, I Ahmad, et al.
Physical Review Letters|February 21, 2006
Breakdown of K selection in 178HfA B Hayes, D Cline, C Y Wu, et al.
Pageof 124